Albireo reveals $385K price tag for newly approved pruritis drug; Jennifer Doudna's Caribou upsizes IPO
Albireo scored a big breakthrough when it won approval by the FDA and EMA this week for Bylvay (odevixibat), the first drug approved to treat pruritus in patients suffering from all forms of progressive familial intrahepatic cholestasis. And they wasted no time in rolling out a jaw-dropping price. In a call with analysts on Wednesday, company execs outlined a weight-based approach they say will create an average per-patient price of $385,000.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.